HRP20120934T1 - Sastavi i postupci koji koriste anti-cs1 antitijela u lijeäśenju multiplog mijeloma - Google Patents
Sastavi i postupci koji koriste anti-cs1 antitijela u lijeäśenju multiplog mijeloma Download PDFInfo
- Publication number
- HRP20120934T1 HRP20120934T1 HRP20120934TT HRP20120934T HRP20120934T1 HR P20120934 T1 HRP20120934 T1 HR P20120934T1 HR P20120934T T HRP20120934T T HR P20120934TT HR P20120934 T HRP20120934 T HR P20120934T HR P20120934 T1 HRP20120934 T1 HR P20120934T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- therapeutic agents
- use according
- decrease
- urine
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims 18
- 229940124597 therapeutic agent Drugs 0.000 claims 17
- 101710085938 Matrix protein Proteins 0.000 claims 8
- 101710127721 Membrane protein Proteins 0.000 claims 8
- 102100032965 Myomesin-2 Human genes 0.000 claims 8
- 210000002700 urine Anatomy 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 5
- 230000029142 excretion Effects 0.000 claims 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (12)
1. Humanizirano anti-CS1 lgGl antitijelo i jedan ili dva terapeutska agensa za istovremenu, odvojenu ili sekvencijalnu upotrebu u liječenju multiplog mijeloma, naznačeni time da spomenuto antitijelo ima sekvencu SEQ ID NO:5 u varijabilnoj regiji teškog lanca i sekvencu SEQ ID NO:6 u varijabilnoj regiji lakog lanca, i da su jedan ili dva spomenuta terapeutska agensa deksametazon ili deksametazon i talidomid.
2. Antitijelo ijedan ili dva terapeutska agensa za upotrebu prema zahtjevu 1, naznačeni time da se spomenuto antitijelo daje intravenozno u dozama od oko 0,5mg/kg do oko 20mg/kg.
3. Antitijelo ijedan ili dva terapeutska agensa za upotrebu prema zahtjevu 1 ili zahtjevu 2, naznačeni time da spomenuto antitijelo i jedan ili dva terapeutska agensa izazivaju kompletan odgovor, pri čemu je kompletan odgovor definiran tako da M-protein nije otkriven u serumu ili urinu imunofiksacijom najmanje 6 tjedana i da je u koštanoj srži otkriveno manje od 5% plazma ćelija.
4. Antitijelo ijedan ili dva terapeutska agensa za upotrebu prema zahtjevu 1 ili zahtjevu 2, naznačeni time da spomenuto antitijelo i jedan ili dva terapeutska agensa izazivaju smanjenje M-proteina veće od 90%.
5. Antitijelo ijedan ili dva terapeutska agensa za upotrebu prema zahtjevu 1 ili zahtjevu 2, naznačeni time da spomenuto antitijelo i jedan ili dva terapeutska agensa izazivaju smanjenje razine seruma M-proteina veće od 50% i/ili smanjenje od 90% u izlučivanju slobodnih teških lanaca u urinu ili smanjenje do ispod 200mg/24h tijekom 6 tjedana.
6. Antitijelo ijedan ili dva terapeutska agensa za upotrebu prema zahtjevu 1 ili zahtjevu 2, naznačeni time da spomenuto antitijelo i jedan ili dva terapeutska agensa izazivaju smanjenje razine seruma M-proteina od 25-49% i/ili smanjenje od 50-89% u izlučivanju slobodnih teških lanaca u urinu koje i dalje prekoračuje 200mg/24h tijekom 6 tjedana.
7. Upotreba humaniziranog anti-CS1 lgGl antitijela i jednog ili dva terapeutska agensa za proizvodnju lijeka za liječenje multiplog mijeloma, naznačena time da spomenuto antitijelo u varijabilnoj regiji teškog lanca ima sekvencu SEQ ID NO:5 i u varijabilnoj regiji lakog lanca sekvencu SEQ ID NO:6, i da su spomenuti terapeutska agensi deksometazon ili deksometazon i talidomid.
8. Upotreba prema zahtjevu 7, naznačena time da se spomenuto antitijelo daje intravenozno u dozama od oko 0,5mg/kg do oko 20mg/kg.
9. Upotreba prema zahtjevu 7 ili zahtjevu 8, naznačena time da spomenuto antitijelo i jedan ili dva terapeutska agensa izazivaju kompletan odgovor, pri čemu je kompletan odgovor definiran time da M-protein nije otkriven u serumu ili urinu imunofiksacijom najmanje 6 tjedana i daje manje od 5% plazma ćelija otkriveno u koštanoj srži.
10. Upotreba prema zahtjevu 7 ili zahtjevu 8, naznačena time da spomenuto antitijelo i jedan ili dva terapeutska agensa izazivaju smanjenje M-proteina veće od 90%.
11. Upotreba prema zahtjevu 7 ili zahtjevu 8, naznačena time da spomenuto antitijelo i jedan ili dva terapeutska agensa izazivaju smanjenje razine M-proteina veće od 50% i/ili smanjenje od 90% u izlučivanju slobodnih lakih lanaca u urinu ili smanjenje do ispod 200mg/24h tijekom 6 tjedana.
12. Upotreba prema zahtjevu 7 ili zahtjevu 8, naznačena time da spomenuto antitijelo i jedan ili dva terapeutska agensa izazivaju smanjenje razine seruma M-proteina od 25- 49% i/ili smanjenje od 50-89% u izlučivanju slobodnih lakih lanaca u urinu koje i dalje prekoračuje 200mg/24h tijekom 6 tjedana.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83625006P | 2006-08-07 | 2006-08-07 | |
| US85614406P | 2006-11-01 | 2006-11-01 | |
| PCT/US2007/075401 WO2008019376A2 (en) | 2006-08-07 | 2007-08-07 | Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120934T1 true HRP20120934T1 (hr) | 2012-12-31 |
Family
ID=39033619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120934TT HRP20120934T1 (hr) | 2006-08-07 | 2012-11-19 | Sastavi i postupci koji koriste anti-cs1 antitijela u lijeäśenju multiplog mijeloma |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7842293B2 (hr) |
| EP (2) | EP2425849A3 (hr) |
| JP (4) | JP2010500370A (hr) |
| AU (1) | AU2007281682B2 (hr) |
| BR (1) | BRPI0716475A2 (hr) |
| CA (1) | CA2660102C (hr) |
| CY (1) | CY1113309T1 (hr) |
| DK (1) | DK2068930T3 (hr) |
| ES (1) | ES2391790T3 (hr) |
| HK (1) | HK1129849A1 (hr) |
| HR (1) | HRP20120934T1 (hr) |
| IL (1) | IL196920A (hr) |
| MX (1) | MX2009001440A (hr) |
| NO (1) | NO345083B1 (hr) |
| NZ (1) | NZ574979A (hr) |
| PL (1) | PL2068930T3 (hr) |
| PT (1) | PT2068930E (hr) |
| WO (1) | WO2008019376A2 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0716647A2 (pt) * | 2006-08-07 | 2017-05-16 | Dana Farber Cancer Inst Inc | processos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-cs1 |
| MX2009001440A (es) * | 2006-08-07 | 2009-04-15 | Pdl Biopharma Inc | Composiciones y metodos que utilizan anticuerpos anti-cs1 para tratar mieloma multiple. |
| US9096681B2 (en) * | 2008-06-02 | 2015-08-04 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides |
| KR20110096536A (ko) * | 2008-10-31 | 2011-08-30 | 애보트 바이오테라퓨틱스 코포레이션 | 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도 |
| EP2785731B1 (en) | 2011-11-30 | 2019-02-20 | AbbVie Biotechnology Ltd | Vectors and host cells comprising a modified sv40 promoter for protein expression |
| AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| JP6374392B2 (ja) | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| WO2015069785A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| US20160264670A1 (en) | 2013-11-06 | 2016-09-15 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| AU2015339012B2 (en) | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
| EA201791049A1 (ru) | 2014-12-04 | 2017-10-31 | Бристол-Майерс Сквибб Компани | Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы) |
| ES2886657T3 (es) * | 2015-06-29 | 2021-12-20 | Bristol Myers Squibb Co | Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| KR20220092578A (ko) | 2019-11-05 | 2022-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | M-단백질 검정 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112969A (en) | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| WO1996037208A1 (en) | 1995-05-25 | 1996-11-28 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| EP2069478A2 (en) | 2006-08-07 | 2009-06-17 | PDL BioPharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| BRPI0716647A2 (pt) | 2006-08-07 | 2017-05-16 | Dana Farber Cancer Inst Inc | processos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-cs1 |
| MX2009001440A (es) * | 2006-08-07 | 2009-04-15 | Pdl Biopharma Inc | Composiciones y metodos que utilizan anticuerpos anti-cs1 para tratar mieloma multiple. |
-
2007
- 2007-08-07 MX MX2009001440A patent/MX2009001440A/es active IP Right Grant
- 2007-08-07 AU AU2007281682A patent/AU2007281682B2/en active Active
- 2007-08-07 CA CA2660102A patent/CA2660102C/en active Active
- 2007-08-07 DK DK07840744.2T patent/DK2068930T3/da active
- 2007-08-07 BR BRPI0716475A patent/BRPI0716475A2/pt not_active Application Discontinuation
- 2007-08-07 EP EP11176209A patent/EP2425849A3/en not_active Withdrawn
- 2007-08-07 PT PT07840744T patent/PT2068930E/pt unknown
- 2007-08-07 ES ES07840744T patent/ES2391790T3/es active Active
- 2007-08-07 EP EP07840744A patent/EP2068930B1/en active Active
- 2007-08-07 NZ NZ574979A patent/NZ574979A/en unknown
- 2007-08-07 PL PL07840744T patent/PL2068930T3/pl unknown
- 2007-08-07 JP JP2009523966A patent/JP2010500370A/ja not_active Withdrawn
- 2007-08-07 WO PCT/US2007/075401 patent/WO2008019376A2/en active Application Filing
- 2007-08-07 US US11/835,245 patent/US7842293B2/en active Active
-
2009
- 2009-02-05 IL IL196920A patent/IL196920A/en active Protection Beyond IP Right Term
- 2009-03-03 NO NO20090969A patent/NO345083B1/no unknown
- 2009-10-21 HK HK09109699.6A patent/HK1129849A1/xx unknown
-
2010
- 2010-10-12 US US12/903,051 patent/US20110165154A1/en not_active Abandoned
-
2012
- 2012-10-31 CY CY20121101037T patent/CY1113309T1/el unknown
- 2012-11-19 HR HRP20120934TT patent/HRP20120934T1/hr unknown
-
2013
- 2013-08-30 JP JP2013178996A patent/JP5775125B2/ja active Active
-
2015
- 2015-04-01 JP JP2015074786A patent/JP6005205B2/ja active Active
-
2016
- 2016-04-06 US US15/091,977 patent/US20160206734A1/en not_active Abandoned
- 2016-09-05 JP JP2016172453A patent/JP2017025077A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008019376A2 (en) | 2008-02-14 |
| JP2015157823A (ja) | 2015-09-03 |
| ES2391790T3 (es) | 2012-11-29 |
| NZ574979A (en) | 2012-06-29 |
| DK2068930T3 (da) | 2012-10-29 |
| JP2014040421A (ja) | 2014-03-06 |
| WO2008019376A3 (en) | 2008-07-10 |
| US20160206734A1 (en) | 2016-07-21 |
| BRPI0716475A2 (pt) | 2016-05-03 |
| PL2068930T3 (pl) | 2013-02-28 |
| MX2009001440A (es) | 2009-04-15 |
| HK1129849A1 (en) | 2009-12-11 |
| CA2660102C (en) | 2017-02-21 |
| JP6005205B2 (ja) | 2016-10-12 |
| EP2425849A3 (en) | 2012-05-09 |
| IL196920A (en) | 2013-11-28 |
| EP2425849A2 (en) | 2012-03-07 |
| JP2017025077A (ja) | 2017-02-02 |
| AU2007281682A1 (en) | 2008-02-14 |
| PT2068930E (pt) | 2012-10-23 |
| EP2068930B1 (en) | 2012-09-19 |
| JP5775125B2 (ja) | 2015-09-09 |
| US20080124332A1 (en) | 2008-05-29 |
| AU2007281682B2 (en) | 2013-05-16 |
| CA2660102A1 (en) | 2008-02-14 |
| JP2010500370A (ja) | 2010-01-07 |
| NO345083B1 (no) | 2020-09-21 |
| EP2068930A2 (en) | 2009-06-17 |
| US7842293B2 (en) | 2010-11-30 |
| IL196920A0 (en) | 2011-08-01 |
| NO20090969L (no) | 2009-04-28 |
| CY1113309T1 (el) | 2016-04-13 |
| US20110165154A1 (en) | 2011-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120934T1 (hr) | Sastavi i postupci koji koriste anti-cs1 antitijela u lijeäśenju multiplog mijeloma | |
| HRP20201505T1 (hr) | Široko neutralizirajuća anti-hiv protutijela | |
| HRP20191999T1 (hr) | Monoklonska protutijela anti-faktora xi i postupci njihove uporabe | |
| JP2010500370A5 (hr) | ||
| HRP20191034T1 (hr) | Pripravci koji sadrže anti-cd38 protutijela i lenalidomid | |
| HRP20190008T4 (hr) | Prevencija i liječenje sinukleinopatske i amiloidogene bolesti | |
| HRP20160131T1 (hr) | Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba | |
| JP2017052784A5 (hr) | ||
| HRP20190917T1 (hr) | NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE | |
| NZ595235A (en) | Compositions and methods for increasing muscle growth | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| JP2015514110A5 (hr) | ||
| RS53072B (en) | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 | |
| JP2010500371A5 (hr) | ||
| RU2020129387A (ru) | Антитела к pd-1 собак | |
| MY149630A (en) | Antibodies against amyloid-beta peptide | |
| JP2009532378A5 (hr) | ||
| NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
| RS53901B1 (en) | PREVENTION AND TREATMENT OF COMPLEMENTS OF THE EYE DISEASE | |
| HRP20210778T1 (hr) | Neutralizacija inhibitornih putova u limfocitima | |
| WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
| CA2813849C (en) | Secukinumab for use in the treatment of ankylosing spondylitis | |
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| PE20061324A1 (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
| JP2018521691A5 (hr) |